|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
GYN: OvaCheckFrom: art fougner, md (evsono@pipeline.com)Thu Mar 25 09:07:53 2004
February 7, 2004 Society of Gynecologic Oncologists Statement Regarding OvaCheck™ The Society of Gynecologic Oncologists (SGO) recognizes the importance of accurate early detection biomarkers for ovarian cancer. For this reason, SGO reviewed the literature regarding OvaCheck, a serum-based diagnostic test for ovarian cancer. In the opinion of SGO, more research is needed to validate the test’s effectiveness before offering it to the public. SGO is committed to actively following and contributing to this vitally important research. As physicians who care only for women with gynecologic cancers, our hope is that these cancers can either be prevented or detected early. Because no test now exists to routinely detect ovarian cancer in its earliest and most curable stages, we will await the results of further clinical validation of OvaCheck with great interest. art
-- art fougner, md ich bin ein New Yorker
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Thu Oct 2 04:45:55 2008 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.